ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL
Two Onc Docs
00:00
Critiques and interpretation of the trial
Kareen discusses limitations: control arm relevance, long PFS needed, and sequencing concerns.
Play episode from 07:10
Transcript
